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Colon cancerThe role of Hedgehog-Gli (Hh-Gli) signaling in colon cancer tumorigenesis has not yet been completely elucidat-
ed. Here we provide strong evidence of Hh-Gli signaling involvement in survival of colon cancer cells, with the
main trigger of activation being deregulated GSK3β.
Our clinical data reveals high expression levels of GSK3β and Gli3 in human colon cancer tissue samples, with
positive correlation between GSK3β expression and DUKES' stage. Further experiments on colon cancer cell
lines have shown that a deregulated GSK3β upregulates Hh-Gli signaling and positively affects colon cancer
cell survival. We show that inhibition of GSK3βwith lithium chloride enhances Gli3 processing into its repressor
form, consequently downregulating Hh-Gli signaling, reducing cell proliferation and inducing cell death. Analysis
of the molecular mechanisms revealed that lithium chloride enhances Gli3–SuFu–GSK3β complex formation
leading to more efﬁcient Gli3 cleavage and Hh-Gli signaling downregulation. This work proposes that activation
of the Hh-Gli signaling pathway in colon cancer cells occurs non-canonically via deregulated GSK3β. Gli3 seems
to be the main pathway effector, highlighting the activator potential of this transcription factor, which is highly
dependent on GSK3β function and ﬁne tuning of the Gli3–SuFu–GSK3β platform.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The Hh-Gli signaling pathway acts as amitogen,morphogen and dif-
ferentiation factor in embryonic development and is involved in major
processes during gastrointestinal (GI) development [1,2]. The canonical
pathway is activated by binding of the ligand Hedgehog (Hh) to the
transmembrane receptor Patched (Ptch), which triggers their internali-
zation. As a consequence, Smoothened (Smo) is translocated to the cell
membrane where it triggers a signaling cascade, ultimately leading to
the release of Gli transcription factors from SuFu and its translocation
to the nucleus. Gli1 is an activator of the pathway, while Gli2 and Gli3
act as activators or repressors, depending on the cellular context [3].
In the absence of Hh signal, Gli1 is degraded, while Gli2 and Gli3 are
processed into transcriptional repressors [4–6]. Hh-Gli signaling targeticine, Rudjer Boskovic Institute,
.sabol@irb.hr (M. Sabol),
ail.com (M. Martinić),
snjezana.ramic@zg.t-com.hrgenes are involved in proliferation and differentiation, cell survival,
self-renewal, angiogenesis, and autoregulation of the pathway [7–9].
SuFu, a negative regulator of the pathway, binds Gli proteins and
prevents their translocation to the nucleus [10,11]. It interacts with a
conserved motif on the Gli protein, and enables Gli phosphorylation
by PKA, GSK3β and CK1 [12]. GSK3β is a multifunctional serine/threo-
nine kinase involved in metabolic and developmental pathways, and
many cellular functions such as stem cell differentiation, self-renewal
and apoptosis [13]. The role of GSK3β in the Hh-Gli signaling pathway
is twofold: phosphorylation of Gli proteins, tagging them for degrada-
tion and processing into repressor forms in the inactive state, or binding
SuFu in ligand-stimulated cells and enabling the release of Gli from the
complex [14]. GSK3β is mainly regulated through posttranslational
phosphorylation events, an activating phosphorylation at Tyr216 and
an inhibitory phosphorylation at Ser9 [15]. Under resting conditions
GSK3β is constitutively active and its activity is regulated through a bal-
ance between the levels of activating and inhibiting phosphorylations
[16–18].
In some cancer types, inactivation ofGSK3β leads to tumorigenesis. In
contrast to its tumor-suppressing activity in these cell types, GSK3β
protein overexpression and pro-survival role have been found in several
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and its active isoform were reported in colon cancer tumors compared
with normal tissues, while the inactive form, phosphorylated at Ser9,
was mostly detected in non-neoplastic tissues [20]. Even though the re-
sults suggest that GSK3βmay participate in colon cancer development,
the mechanism has not been discovered. Here we describe a potential
mechanism underlying the oncogenic role of GSK3β through deregula-
tion of the Hh-Gli signaling pathway. By keeping it in an active state, it
contributes to colon cancer cell proliferation.2. Materials and methods
2.1. Colon cancer tissue samples
Twenty tissue samples from colon carcinoma patients were
collected from the Clinical Hospital Center Zagreb. Relevant clinical
data is listed in Table 1. All experiments were performed in accor-
dance with the Declaration of Helsinki, and the Ethical Committee
of Clinical Hospital Center Zagreb no. 01/001/VG (dated November
29, 2010) approved the study. Tissue samples were routinely
parafﬁnized and sliced into 5 μm sections for immunohistochemical
staining.2.2. Immunohistochemistry
Parafﬁn slides were deparafﬁnized, rehydrated and boiled in Target
Retrieval solution (Dako, S2367) using PTlink (Dako). Primary antibod-
ies anti-Shh (sc-9024), anti-Ptch1 (sc-6147), anti-Smo (sc-13,943),
anti-SuFu (sc-10,933), anti-GSK3β (sc-8257), anti-Gli1 (sc-20,687),
anti-Gli2 (sc-20,291) and anti-Gli3 (sc-20,688) from Santa Cruz Bio-
technology (SCBT)were used at a 1:50 dilution,+4 °C, overnight. Slides
were stained on the Dako autostainer using the Dako LSAB+/HRP kit
(Dako, K0679). For negative control, slides were treated identically,
omitting the primary antibody step. Slides were visualized using the
Olympus CX41 RFmicroscope and imageswere takenwith theOlympus
Digital camera C-5060.
Relative DAB staining intensity was quantiﬁed using a cyan-
magenta-yellow-black (CMYK) color model adapted from Pham
et al.[21], which was successfully applied in several studies [22,23].Table 1
Relevant clinical data for the colon carcinoma patients.
Sample no. Diagnosis Grade DUKES'
Sample no. Diagnosis Grade DUKES'
1 Ca sygmae 1 B
2 Ca coli ascedens 1 B
3 Ca sygmae 1 C
4 Ca recti 1 C
5 Ca sygmae 1 A
6 Ca coli transversi 1 C
7 Ca coli transversi 1 D
8 Ca recti 1 C
9 Ca coli descedens 1 C
10 Ca sygmae 3 C
11 Ca coli ascedens 1 C
12 Ca coli ascedens 1 A
13 Ca sygmae 1 C
14 Ca coli ascedens 1 B
15 Ca sygmae 1 D
16 Ca coeci 1 A
17 Ca sygmae 1 C
18 Ca recti 1 B
19 Ca sygmae 1 A
20 Ca recti 1 C
a CEA — carcinoembryonic antigen.2.3. Cell culture
SW480, HCT116 and Caco-2 colon cancer cell lines, derived frompri-
mary colorectal adenocarcinomas and the SW620 cell line, derived from
a metastasis of the primary tumor from which SW480 was derived,
were used for cell culture experiments. Cells were cultured in
Dulbecco's Minimal Essential Medium (DMEM) supplemented with
10% fetal bovine serum (PAA), 200 mM of sodium pyruvate and 2 mM
of L-glutamine, and were maintained in a humidiﬁed 5% CO2 environ-
ment. For gene and protein expression experiments, 24 h after seeding,
cells were treated with 10 μM of cyclopamine (Toronto Research
Chemicals) for 48 h, 20–40 mM of lithium chloride (LiCl) (Kemika) for
24 and 48 h, 0.5 μMof SAG (SCBT) for 24 h,with DMSO treatment as ve-
hicle control. For the analysis of the effect of SAG on GSK3β Ser9 phos-
phorylation, cells were treated with DMSO as vehicle control, 30 mM
of LiCl, 0.5 μM of SAG, 1 μM of SAG and combined treatments of
30 mM of LiCl with 0.5 μM of SAG or 1 μM of SAG for 24 h. For analysis
of caspase-3 and PARP cleavage cells were treated with 20–40 mM of
LiCl for 72 h. For analysis of LC3 processing cellswere treatedwith either
30 mM of LiCl, 30 mM of LiCl after 1 h of pre-incubation with 10 mM of
ammonium-chloride (NH4Cl) (Kemika) or 10 mM of NH4Cl alone for
4 h.
2.4. GSK3β silencing
Cells in 6-well plates were transfected with 50 nM of GSK3β siRNA
(sc-35,527, SCBT) or Silencer Negative Control #1 siRNA (Life Technolo-
gies) using siPORT NeoFX (Life Technologies) transfection reagent. The
mediumwas changed after 24 h, and cells were collected after an addi-
tional 24 h.
2.5. Cell proliferation assay
Cell proliferation and viability was determined using MTT assay.
Brieﬂy, cells in 96-well plates were treated in quadruplicates for 72 h
with 2.5–15 μM of Smo inhibitor cyclopamine or 10–50 mM of GSK3β
inhibitor LiCl. The effect of SAG (0.25, 0.5, 1 and 2 μM) was analyzed
after 24, 48 and 72 h. To analyze if SAG can rescue the effect of LiCl,
cells were treated simultaneously with LiCl (30 mM or 40 mM) and in-
creasing concentrations of SAG (0.25, 0.5, 1 and 2 μM) for 24, 48 andAge Positive lymph nodes CEAa Size
Age Positive lymph nodes CEAa Size
73 0 3 42 mm
78 0 3,2 50 mm
73 1 4,49 40 mm
59 1 1,82 65 mm
65 0 2,8 46 mm
56 1 10,52 45 mm
79 1 10,22 60 mm
61 1 3,2 45 mm
60 1 2,9 36 mm
50 1 0,98 40 mm
70 1 3 40 mm
53 0 1,6 62 mm
70 1 3,6 40 mm
49 0 2,2 42 mm
73 1 75,95 42 mm
74 0 2,8 42 mm
70 1 2,14 40 mm
76 0 3,74 40 mm
73 0 3,24 45 mm
58 1 7,66 60 mm
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MTT solution (1 mg/ml) for 4 h. DMSO was used to dissolve the
formazan product. Absorbance was measured at 570 nm.
2.6. Quantitative real-time PCR (qRT-PCR)
RNA was extracted from cells using TRIzol reagent (Invitrogen) ac-
cording to manufacturer's instructions. 1 μg of RNA was reverse tran-
scribed into cDNA using TaqMan Reverse Transcription Reagents
(Applied Biosystems). Gene expression experiments were performed
in the CFX96 real-time PCR machine (Bio-Rad) using Sso Fast EvaGreen
Supermix (Bio-Rad) and the following primers: RPLP0 F 5' GGCACCATTG
AAATCCTGAGTGATGTG 3', RPLP0 R 5' TTGCGGACACCCTCCAGGAAGC 3',
PTCH1 F 5' TCCTCGTGTGCGCTGTCTTCCTTC 3', PTCH1 R 5' CGTCAGAAAG
GCCAAAGCAACGTGA 3', SMO F 5' CTGGTACGAGGACGTGGAGG 3', SMO
R 5' AGGGTGAAGAGCGTGCAGAG 3', GLI1 F 5' GCCGTGTAAAGCTCCAGT
GAACACA 3', GLI1 R 5' TCCCACTTTGAGAGGCCCATAGCAAG 3', SHH F 5'
GAAAGCAGAGAACTCGGTGG 3', SHH R 5' GGTAAGTGAGGAAGTCGCTG
3' [24], SUFU F 5' AACAGCAAACCTGTCCTTCC 3', SUFU R 5' TCAGATGT
ACGCTCTCAAGC 3' [25], GLI2 F 5'-GCCATCAAGACCGAGAGCTC-3', GLI2
R5'-CGGCCCATGAGCAGGAATCC-3' [26], GLI3 F 5'-CACTACCTCAAAGC
GGGAAG-3', GLI3 R 5'-TGTTGGACTGTGTGCCATTT-3' [27], GSK3β F 5'-
GGAGAACTGGTCGCCATCAAG-3', GSK3β R 5'-ACATTGGGTTCTCCTCGG
ACC-3'[28].
2.7. Western blot
Proteins were extracted from cells using RIPA buffer supplemented
with protease inhibitors (Roche) with addition of phosphatase inhibi-
tors (Roche) for phosphorylated protein extraction. Protein concentra-
tion was determined using Bio-Rad Protein Assay (Bio-Rad). For
analysis, 50 μg of protein was used. Membranes were blocked in 5%
milk. Primary antibodies against Gli3 (sc-20,688, SCBT; AF-3690, R&D
Systems; 19,949–1-AP, ProteinTech), GSK3β (#9832, Cell Signaling
Technology (CST)), phospho-Ser9 GSK3β (#5558, CST), Sufu (#2520,
CST) and Ptch1 (sc-6147, SCBT; 17,520–1-AP, ProteinTech) were used.
For LC3 detection the MAP LC3α/β antibody was used (sc-292,354,
SCBT). For apoptosis the anti-PARP (556,362, BD Pharmingen) and the
anti-caspase-3 (sc-7272, SCBT) antibodies were used. Actin (sc-1616,
SCBT) was used as loading control. After washing, membranes were in-
cubatedwith the appropriate secondary HRP-conjugated antibody. Pro-
teins were visualized using Super Signal West Pico and Super Signal
West Femto reagents (Pierce).
2.8. Co-immunoprecipitation
Co-immunoprecipitation was performed using Protein G coated
Dynabeads (Life Technologies) according to themanufacturer's instruc-
tions (Invitrogen, Rev. 005). For Gli3 co-immunoprecipitation 4 μg of
Gli3 antibody (AF-3690, R&D) was used per sample. For SuFu and
GSK3β co-immunoprecipitations, SuFu (#2520, CST) and GSK3β
(#9832, CST) antibodies were used at a 1:25 dilution. Samples were in-
cubated with the Dynabead–antibody complex over night at +4 °C.
Samples were eluted with 1× loading buffer and heated 5 min at 95 °C
before analysis on Western blot.
2.9. Acridine orange staining and ﬂow cytometric analysis
For analysis of AVO, cells grown in triplicate in 12-well plates were
treated with 20, 30 and 40 mM LiCl for 72 h. Then, 2 μg/ml of acridine
orange in serum free medium was added for 30 min, after which the
cells were washed in PBS and trypsinized. Cells were then pelleted, re-
suspended in PBS containing 2 μg/ml of acridine orange and analyzed
by ﬂow cytometry (BD FACSCalibur).2.10. Immunoﬂuorescence
Immunoﬂuorescent staining and confocal microscopy was per-
formed as previously described [29]. Primary antibodies for Gli3 and
GSK3β, were the same as for co-IP experiments. Confocal images were
examined using the Mander's coefﬁcient plug-in of the ImageJ software
(v 1.45e) for co-localization of green and red signals.
2.11. Colony formation assay
103 cells were seeded per well in a 6-well plate. The following day
the cells were treated with 20 and 30 mM of LiCl. Colonies were
grown for 2 weeks and medium with treatment was changed every
three days. Colonies were ﬁxed with formaldehyde and stained using
1% cristal violet.
2.12. Statistical analysis
For gene expression, all experiments were performed at least in du-
plicates and mean values and standard error was calculated for each
data point. For immunohistochemical staining, χ2 test was used to de-
termine the association between variables. One way ANOVA was used
for autophagy analysis and the analysis of difference in co-localization
between untreated samples and each treatment. All two-tailed P-
values less than 0.05 were considered statistically signiﬁcant. The anal-
ysis was performed using MedCalc for Windows version 11.4.2.0
(MedCalc Software, Mariakerke, Belgium).
3. Results
3.1. Tissue expression of GSK3β and Gli3 correlate with clinical parameters
Twenty colon cancer tissue sampleswere stained for Hh-Gli pathway
proteins Ptch, Smo, Gli1, Gli2, Gli3, Shh, SuFu and GSK3β. Of the 20 sam-
ples, 19 samples were of grade I and one sample was a grade III tumor.
According to DUKES' staging the sample set was consisted of tumors
ranging from stage A to stage D (Table 1). GSK3β and Gli3 showed
high staining intensities (2 and 3) in 95% of samples (Fig. 1, Table 2).
90% of samples showed no Smo staining and 65% no Ptch staining
(Table 2). Staining intensities were compared with several clinical pa-
rameters: DUKES' stage, positivity of surrounding lymph nodes, or
carcinoembryonic antigen (CEA) expression. Fifteen lymph nodes were
examined for each of the patients, and a positive score was given if at
least one of them was positive for transformed cells. GSK3β staining
was correlatedwithDUKES' stage (P=0.034)with higher DUKES' stages
more strongly stained for GSK3β. For Gli3, a similar trendwas visible, but
not statistically signiﬁcant (P = 0.058). The sample number needs to be
increased in order to conﬁrm the correlation of Gli3 and DUKES' stage,
but the obtained results suggest a pro-tumorigenic role for GSK3β in
these samples.
3.2. Hh-Gli pathway is active in human colon cancer cells
Four colon cancer cell lines (SW480, SW620, HCT116 and Caco-2)
were tested for the presence of GSK3β and other Hh-Gli signaling com-
ponents. Since HCT116 and Caco-2 did not express GLI3 (Fig. 2A), which
according to the results on clinical samples possibly plays a role in colon
cancer, we continued our research with SW480 and SW620 cells. We
found SHH, PTCH1, SMO, GSK3β, SUFU and GLI3 expressions in both cell
lines,whileGLI1 andGLI2 expressionswereweaker (Fig. 2A). To conﬁrm
the activity of the pathway in these cell lines we tested their respon-
siveness to the Hh-Gli pathway agonist SAG, as well as a Hh-Gli in-
hibitor, cyclopamine. The pathway was stimulated in both cell lines
after treatment with SAG. SAG induced PTCH1 and GLI1 expression
but with different modalities in the two cell lines. PTCH1 induction
was more pronounced in SW480 cells, whereas GLI1 induction was
Fig. 1. Immunohistochemical staining of Gli1, Gli2, Gli3, GSK3β, Hh, Ptch, Smo and SuFu in colon cancer tissue samples. Gli3 and GSK3β show the highest staining intensity. Scale bar rep-
resents 100 μm.
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ulation of GLI2 and GLI3 genes (Fig. 2B). SAG also affected cell prolifera-
tion in a dose dependent manner, the proliferation rates of both cell
lines increased with increasing SAG concentrations. This effect was
more pronounced at the earlier time points, when SAG was shown to
have an effect on Hh-Gli signaling activity (Fig. 2 C, D). Cyclopamine, a
pathway inhibitor, on the other hand, did not have an inhibitory effect
on Hh-Gli pathway activity. On the contrary, it slightly increased
PTCH1 and GLI1 expression levels in SW480 cells, and had no effect
on target gene expression levels in SW620 cells (Fig. 2E). Cyclopamine
also had no effect on cell proliferation in either cell line (Fig. 2F).
These results suggest that the pathway can be additionally activated,
but inhibition at the level of Smo is not functional.Table 2
Relative staining intensities of tested proteins in colon carcinoma clinical samples. Intensities w
Staining intensity PTCH SMO GLI1 GLI2
No. % No. % No. % No.
0 13 65% 18 90% 6 30% 9
1 4 20% 2 10% 4 20% 4
2 0 0% 0 0% 3 15% 3
3 3 15% 0 0% 7 35% 4
Total 20 100% 20 100% 20 100% 203.3. Inhibition of GSK3β with LiCl downregulates Hh-Gli signaling and
inhibits cell proliferation, whereas GSK3β knock-down upregulates Hh-Gli
signaling
We tested the impact of GSK3β inhibitionwith LiCl on Hh-Gli signal-
ing in SW480 and SW620 cells, as high GSK3β expression in clinical
samples and unresponsiveness of the cell lines to the Smo inhibitor
cyclopamine were indicative of GSK3β deregulation. GSK3β proved es-
sential for colon cancer cell proliferation and survival, since after treat-
ment with LiCl proliferation of both cell lines decreased in a dose-
dependent manner (Fig. 3A). The ability of both cell lines to form colo-
nies was decreased as well, and although 20 mM of LiCl affected colony
formation only slightly, 30 mM of LiCl inhibited clonogenic potentialere determined using the CMYK color model as described by Pham et al.[21].
GLI3 HH SUFU GSK3β
% No. % No. % No. % no. %
45% 1 5% 5 25% 5 25% 1 5%
20% 0 0% 5 25% 6 30% 0 0%
15% 5 25% 3 15% 4 20% 3 15%
20% 14 70% 7 35% 5 25% 16 80%
100% 20 100% 20 100% 20 100% 20 100%
Fig. 2.Hh-Gli signaling is active in human colon cancer cell lines. (A) Basal levels of Hh-Gli components expression normalized relative to expression of the housekeeping gene RPLP0 and
shown as 2−ΔCt values on logarithmic scale. (B) Effects of 0.5 μMSAG (24 h) onHh-Gli target gene (PTCH1, GLI1),GLI2 and GLI3 expression relative to expression in control cells with value
of 1 (emboldened line). (C, D) SAG increases cell proliferation rates of SW480 and SW620 cell lines. (E) Effects of 10 μM cyclopamine (48 h) on Hh-Gli target gene expression relative to
non-treated conditions with value 1 (emboldened line). (F) Effect of increasing doses of cyclopamine on cell proliferation, measured after 72 h.
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Gli signaling downregulation (Fig. 3C). The Hh-Gli target gene GLI1
was efﬁciently decreased in both cell lines, whereas PTCH1 gene expres-
sion was downregulated in SW480 but remained unaffected in SW620
cells. Nevertheless, Western blot analysis conﬁrmed decreased Ptch1
protein levels after treatment in both cell lines (Fig. 3D). At the level
of Gli transcription factors, we observed signiﬁcant changes in the equi-
librium of Gli3 full length (Gli3FL) and repressor (Gli3R) forms after
GSK3β inhibition. In untreated cells, both the Gli3FL and Gli3R forms
were present in equal amounts, but after LiCl treatment increased pro-
cessing of Gli3 protein into its repressor form occurred in both cell
lines (Fig. 3E). A decrease in Gli3FL levels, and increasing Gli3R levels,
indicate Gli3R as the main inhibitory switch after GSK3β inhibition.
In contrast to inhibiting GSK3βwith LiCl, knock-down of its expres-
sion in SW480 cells had an opposite effect on Hh-Gli signaling. Gli3FL
and Ptch1 protein expression levels were upregulated upon GSK3β
knock-down, indicating pathway activation (Fig. 3F).
Interestingly, we have shown that the effects of LiCl (30 mM and
40 mM) on the proliferation rates of both cell lines can be rescued by
simultaneously stimulating the Hh-Gli signaling pathway. Again, theFig. 3. LiCl inhibits cell proliferation and downregulates Hh-Gli signaling. (A) LiCl inhibits SW4
formation ability of SW480 and SW620 cells; 30 mM of LiCl inhibits this ability almost comple
levels of target gene expression.Data are represented as fold change (2−ΔΔCt) relative to control
levels of Ptch1protein after 20mMof LiCl treatment. (E)Western blot showing that 20mMof Li
down increases Ptch1 and Gli3FL levels. (G, H) Simultaneous stimulation of Hh-Gli signaling wi
both cell lines. The effects are most pronounced at earlier time points when SAG has the stroneffect was more pronounced at earlier time points, when the effect of
SAG on Hh-Gli signaling is strongest (Fig. 3G, H).
3.4. LiCl enhances Gli3 cleavage by restoring GSK3β function
The Ser9 phosphorylation of GSK3β is lost in colon cancer cell lines,
whereas the activating Tyr216 phosphorylation remains [20]. LiCl is
known for promoting the inhibitory Ser9 phosphorylation of GSK3β
[30], so we checked the Ser9 phosphorylation status of GSK3β in
SW480 and SW620 cells before and after treatment with LiCl compared
to total GSK3β levels. Total GSK3β levels remained constant regardless
of treatment status but the phosphorylated Ser9 fraction of GSK3β in-
creased after treatment with LiCl (Fig. 4A). We have also shown that
stimulating the Hh-Gli signaling pathway with SAG mildly decreases
the Ser9 phosphorylated fraction of GSK3β in both cell lines (Fig. 4B),
which is in accordance with the observed upregulation of Hh-Gli activ-
ity (Fig. 2B). Interestingly, SAG is also able to rescue the effect of LiCl on
GSK3β Ser9 phosphorylation in both cell lines, shown by a decreased
Ser9 phosphorylated fraction of GSK3βwhen SAG is added to LiCl, com-
pared with LiCl alone (Fig. 4B). This result conﬁrms that the increase in80 and SW620 cell proliferation in a dose-dependent manner. (B) LiCl affects the colony
tely. (C) 20 mM of LiCl downregulates Hh-Gli pathway activity as indicated by decreased
cellswith the value of 1, plotted on logarithmic scale. (D)Western blot showing decreasing
Cl enhancesGli3 protein processing into repressor form inboth cell lines. (F) GSK3β knock-
th SAG can rescue the inhibiting effect of LiCl (30 and 40mM) on cell proliferation rates of
gest effect on Hh-Gli signaling.
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decrease of Hh-Gli signaling and cellular proliferation, and that SAG
can rescue the effects of LiCl by modifying the Ser9 phosphorylation of
GSK3β. To check whether LiCl is able to restore the ability of GSK3β to
phosphorylate Gli3, we tested the dynamics of the SuFu–Gli3–GSK3β
complex formation after treatment, which is essential for proper Gli3
phosphorylation and cleavage. Immunoﬂuorescent staining of GSK3β
and Gli3 in SW480 and SW620 cells indicated changes in localization
of these proteins in relation to each other after treatment with LiCl. In
non-treated cells Gli3 was found both in the nucleus and cytoplasm,
whereas GSK3β was located in the cytoplasm. Although there was a
basal level of co-localization between these two proteins, an increase
in co-localization was detected after treatment with 20 mM of LiCl for
16 h, implying that under these conditions GSK3βmight phosphorylate
Gli3 more efﬁciently than in non-treated conditions (Fig. 4C). Co-
immunoprecipitation analyses in SW480 cells conﬁrmed that indeed,
SuFu binds Gli3, as well as GSK3βmore efﬁciently after LiCl treatment.
This complex already forms 10 h after treatment, whereas 24 h post-
treatment Gli3 is already efﬁciently cleaved (Figs. 4D, 3E).
3.5. Inhibition of Hh-Gli signaling with LiCl induces autophagy and
apoptosis
To determine the mechanism of cell death that occurs after inhibi-
tion with LiCl we tested the cells for autophagy and apoptosis.
Acridine-orange staining revealed that this treatment signiﬁcantly in-
duced acidic vesicular organelle (AVO) formation in a dose-dependent
manner (Fig. 5A, B), which is a characteristic of autophagy. To check
whether autophagic ﬂux is occurring, LC3 processing after LiCl treat-
ment was analyzed, in the presence and absence of NH4Cl, a lysosomal
protease inhibitor. In SW480 cells 30 mM of LiCl did not increase LC3-
II levels, but addition of NH4Cl signiﬁcantly increased LC3-II levels. No
increase in LC3-II levels after LiCl treatment indicates that intra-
autophagosomal LC3-II becomes rapidly degraded in autolysosomes,
since after blocking lysosomal protease LC3-II levels increase (Fig. 5C)
[31,32]. In SW620 cells however, an increase in LC3-II was visible after
treatment with 30 mM of LiCl, and an additional increase in the pres-
ence of inhibitor. Therefore, these results indicate that autophagic ﬂux
is occurring under these conditions (Fig. 5D). Analysis of caspase-3
and PARP cleavage also indicate apoptosis induction with LiCl in
SW480 cells (Fig. 5E). As for SW620 cells, only cleavage of PARP was
detected at the dose of 40mMof LiCl but not that of caspase-3 (Fig. 5F).
4. Discussion
Colon cancer is the third most commonly diagnosed cancer in males
and the second in females [33]. Despite the efforts to optimize diagnos-
tic processes and improve treatment regimens the mortality rate is still
high [34]. These facts emphasize the need for improving our under-
standing of this disease and thereby provide new insights for future
therapy design. To date several studies have addressed the activation
of Hh-Gli signaling in colon cancer [9,35–37], some describe Gli1 and/
or Gli2 as the main molecular switch in colon carcinogenesis [35,36,
38], while others indicated a key role for Gli3 [37]. We showed expres-
sion of all Hh-Gli signaling components in a set of colon cancer clinical
samples, with GSK3β and Gli3 showing high staining intensities (2
and 3) in 95% of samples. GSK3β expression positively correlated with
DUKES' stage, whereas the same trend was visible for Gli3 although
not statistically signiﬁcant (P = 0.058). It should be noted that our setFig. 4. LiCl increases GSK3β Ser9 phosphorylation and enhances Gli3–GSK3β–SuFu complex fo
treatment compared with total GSK3βwhich remains constant. (B)Western blot of Ser9 phosph
binations of 30mMof LiClwith 0.5 μMof SAG and 1 μMof SAG. SAG itself mildly decreases the S
to rescue the LiCl induced increase in Ser9 phosphorylation. (C) Immunoﬂuorescent analysis of
In untreated cells GSK3β and Gli3 show a basal level of co-localization, mostly diffused. After Li
Scale bars represent 5 μm. Quantiﬁcation of co-localization is shown on graphs next to the ima
binding of Gli3 and Sufu, as well as GSK3β and SuFu after LiCl treatment. Optical density quanof clinical samples was consisted mostly of grade I tumors and only
one sample of grade III colon cancer, with different DUKES' stages.
Therefore, a larger set of samples with higher grade tumors should be
assessed to conﬁrm that these observations are not limited to this
subpopulation of tumors.
Based on clinical data, we decided to investigate the role of GSK3β
andHh-Gli signalingmore closely. In recent years it has become evident
that GSK3β can have an altered, oncogenic role in certain tumor types
[39–41]. This has also been conﬁrmed for colon cancer [16,20], but the
underlying mechanism of its function has not been elucidated. This
study demonstrates a potential mechanism for deregulated GSK3β in
colon cancer cells. We propose that it upregulates the Hh-Gli signaling
pathway, which ensures cancer cell proliferation and survival. We
found active Hh-Gli signaling in two colon cancer cell lines, which did
not respond to classical inhibition with cyclopamine. The inability of
cyclopamine to inhibit the Hh-Gli pathway in these cell lines is in agree-
mentwith observations in another studywhere the authors found com-
ponents of the Hh-Gli signaling pathway in colon cancer cell lines, but
could not inhibit it with cyclopamine [42]. As cyclopamine targets
Smo it is evident that a deregulated GSK3β, which acts downstream of
Smo, could block the effect of cyclopamine. On the other hand, LiCl,
which targets GSK3β, downregulates Hh-Gli signaling. We show that
this is a consequence of enhanced Gli3 processing into transcriptional
repressor form (Gli3R). This, in turn, decreases cell proliferation and
their clonogenic ability. Interestingly, this effect of LiCl on cell prolifera-
tion can be rescued by simultaneously stimulating the Hh-Gli signaling
pathway, indicating a key role for this pathway in regulating prolifera-
tion of these two colon cancer cell lines. Since we showed that the
Ser9-phosphorylated portion of GSK3β increases after LiCl treatment,
we hypothesized, that this event restores the balance between the acti-
vating and inactivating phosphorylation on GSK3β, and enables it to
properly phosphorylate Gli3. We conﬁrmed that the Ser9 phosphoryla-
tion of GSK3β is indeed relevant for the LiCl-dependent decrease of Hh-
Gli signaling activity and cell proliferation, since activation of thepathway
with SAG is able to rescue the LiCl increase of Ser9 phosphorylation in
both colon cancer cell lines. Immunoﬂuorescent staining shows higher
levels of Gli3 and GSK3β co-localization after treatment with LiCl which
implies more efﬁcient Gli3 phosphorylation, which is necessary for it to
become cleaved [43]. This is supported with co-immunoprecipitation
experiments which have shown that LiCl enhances Gli3–SuFu–GSK3β
complex formation and thusGli3 phosphorylation andprocessing (repre-
sented schematically in Fig. 6).
In contrast to inhibiting GSK3βwith LiCl, knock-down of GSK3β led
to Hh-Gli pathway activation, indicating that, in the aspect of treatment,
it is crucial to restore GSK3β function in these cancer cells, rather than
abolish its expression.
We also investigated how cell proliferation decreases after LiCl treat-
ment. After Hh-Gli pathway inhibition with LiCl a signiﬁcant increase in
AVO formation is observed, which characterizes autophagy. Analysis of
LC3 processing supported this ﬁnding, indicating induction of autopha-
gic ﬂux. It is known that lithium itself can activate autophagy through
inhibition of inositol monophosphatase [44], but it remains to be inves-
tigated whether inhibition of Hh-Gli signaling, or more precisely Gli3R,
may play a part as well. As Gli3 becomes processed after LiCl treatment
itmay no longer be able to inhibit autophagy, ormay start repressing in-
hibitors of autophagy. Recent ﬁndings show that Hh-Gli signaling can
regulate autophagy through Gli1 [45] or Gli2 [46]. Both groups found
that inhibition of the pathway induced autophagy whereas activation
of the pathway inhibited it. Even though autophagy is a conservedrmation. (A) Western blot of Ser9 phosphorylated GSK3β showing an increase after LiCl
orylated GSK3β after treatmentwith 30mM of LiCl, 0.5 μMof SAG, 1 μMof SAG and com-
er9 phosphorylated fraction of GSK3β comparedwith vehicle-treated cells, and is also able
Gli3 (red) and GSK3β (green) localization. Nuclei are stainedwith DAPI and shown in blue.
Cl treatment the co-localization rate increases and is localized in distinct perinuclear areas.
ges. (D) Western blot images of co-immunoprecipitation experiments, showing increased
tiﬁcation of bands is shown on graphs below. NC — negative control.
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Fig. 5. LiCl induces autophagy and apoptosis in SW480 and SW620 cells. (A) Dot blot representations of ﬂow cytometric analysis after acridine orange staining of SW480 cells, non-treated
and treated with 20, 30 and 40 mM of LiCl with quantitative analysis shown on graph below. (B) Dot blot representations of ﬂow cytometric analysis after acridine orange staining of
SW620 cells, non-treated and treated with 20, 30 and 40 mM of LiCl with quantitative analysis shown on graph below. (C) Analysis of LC3 processing in SW480 cells after treatment
with LiCl in the absence and in the presence of a lysosmal protease inhibitor. (D) Analysis of LC3 processing in SW620 cells after treatment with LiCl in the absence and in the presence
of a lysosmal protease inhibitor. (E) Western blot analysis of caspase-3 and PARP cleavage indicating induction of apoptosis in SW480 cells after treatment with 30 and 40 mM of LiCl.
(F) Western blot analysis of caspase-3 and PARP cleavage in SW620 cells showing only cleavage of PARP at 40 mM of LiCl.
2582 D. Trnski et al. / Biochimica et Biophysica Acta 1852 (2015) 2574–2584process that enables cell survival under stressful conditions, it can also
lead to cell death under certain conditions [47]. In our case autophagy
results in cell death since a signiﬁcant decrease in cell proliferation is ob-
served. Also, induction of apoptosiswas observed in SW480 cells, which
suggests that autophagy may be providing the energy for the execution
of apoptosis or cooperates with apoptosis to lead to cell death [48].
Gli3R has previously already been shown to increase levels of apoptosis
in colon cancer cells [36]. As for SW620 cells, PARP cleavage was ob-
served, but not that of caspase-3. It is possible that PARP is cleaved by
another caspase that has not been tested [49] or independently of
caspases [50].This work implies that GSK3β is an interesting target for develop-
ment of colon cancer therapeutics. Therapeutics directed toward the re-
establishment of the inhibitory Ser9 phosphorylation are especially of
interest since GSK3β knock-down activates Hh-Gli signaling, leading
to potentially adverse effects. LiCl has been used for many years as ther-
apy formood disorders [51]. In fact, patients that have been treatedwith
lithium for psychological reasons had lower risk of developing cancer
compared with non-treated patients [52]. The problem with lithium is
that it is used in supraphysiological concentrations in in vitro experi-
ments and therefore the doses are not comparable to those used in pa-
tients. Recently, a group of authors reported that a novel GSK3β
Fig. 6. Schematic representation of the proposed events in colon cancer cells before and after treatmentwith LiCl. GSK3β phosphorylated predominantly at Tyr216 is unable to phosphor-
ylate Gli3 which thus stays in its full length activator form. LiCl promotes the Ser9 phosphorylation of GSK3β that restores the balance between the Tyr216 and Ser9 phosphorylation and
enables GSK3β to function properly; it phosphorylates Gli3 and thereby promotes its processing into Gli3R, which downregulates the Hh-Gli pathway.
2583D. Trnski et al. / Biochimica et Biophysica Acta 1852 (2015) 2574–2584inhibitor, CG0009, induces cell death in breast cancer cells by enhancing
the Ser9 phosphorylation, at concentrations much lower than those of
LiCl [53]. On the other hand, blocking the Hh-Gli signaling pathway
downstream of GSK3β may also represent an interesting approach of
inhibiting cancer cell growth. This emphasizes the need for developing
inhibitors speciﬁc for Gli3, which plays an important role in regulating
the Hh-Gli pathway in our model.
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